{"id":"NCT01925768","sponsor":"Amgen","briefTitle":"Safety and Efficacy Study of Apremilast to Treat Psoriatic Arthritis","officialTitle":"A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) Monotherapy in Subjects With Active Psoriatic Arthritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-09-04","primaryCompletion":"2015-02-25","completion":"2016-11-17","firstPosted":"2013-08-20","resultsPosted":"2016-06-13","lastUpdate":"2020-05-12"},"enrollment":219,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Psoriatic Arthritis"],"interventions":[{"type":"DRUG","name":"Apremilast 30 mg","otherNames":["Otezla","CC-10004"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Apremilast 30 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether apremilast is safe and effective for treating patients with psoriatic arthritis.","primaryOutcome":{"measure":"Percentage of Participants Who Achieved an American College of Rheumatology 20% (ACR20) Response at Week 16","timeFrame":"Baseline and Week 16","effectByArm":[{"arm":"Placebo (PBO)","deltaMin":20.2,"sd":null},{"arm":"Apremilast (APR) 30 mg","deltaMin":38.2,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0040"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":71,"countries":["United States","Australia","Canada","Czechia","Estonia","Hungary","New Zealand","Romania","Russia","Spain"]},"refs":{"pmids":["29343507","37316690"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":109},"commonTop":["Diarrhoea","Nasopharyngitis","Upper respiratory tract infection","Nausea","Hypertension"]}}